AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

Delisting riskPopularity #4,543

MDXH · NASDAQ · Medical - Diagnostics & Research

MDxHealth (MDXH)

Molecular prostate-cancer tests for testing and treatment decisions.

$0.5917

vs last close−0.01 (−1.37%)

In millions of USD, except per-share figures

In millions	Q4 FY20Dec 2020	Q2 FY21Jun 2021	Q4 FY21Dec 2021	Q2 FY22Jun 2022	Q4 FY22Dec 2022	Q2 FY23Jun 2023	Q4 FY23Dec 2023	Q2 FY24Jun 2024	Q4 FY24Dec 2024	Q2 FY25Jun 2025	Q4 FY25Dec 2025	Q2 FY26Jun 2026
Revenue	9	11	12	13	24	31	39	42	48	27	55	27
Cost of revenue	5	6	6	7	11	13	14	17	18	9	25	9
Gross profit	3	5	5	6	13	19	25	25	30	18	29	18
	17	18	20	23	34	35	36	39	40	19	41	23
Research & development	2	3	4	4	4	2	1	5	5	3	10	2
	15	15	−7	19	31	29	28	32	32	16	17	20
Selling & marketing	8	8	−6	10	17	18	−12	21	20	10	−23	11
General & administrative	7	7	−2	10	14	11	40	11	12	6	39	8
Other expenses	0	0	23	0	0	4	7	2	3	1	14	1
Operating income	−14	−12	−14	−17	−21	−16	−11	−14	−11	−2	−12	−5
	−1	−1	−1	−1	−5	−6	−10	−6	−7	−6	−8	−4
Interest income	0	0	0	0	0	0	1	2	0	0	−1	2
Interest expense	1	0	1	1	2	3	10	5	7	6	8	6
Other non-operating income	0	0	0	0	4	3	10	−1	0	0	0	−2
Income before tax	−15	−13	−16	−18	−26	−22	−21	−20	−18	−8	−20	−9
Income tax expense	0	0	0	0	0	0	0	0	0	0	−1	0
Net income from continuing operations	−15	−13	−16	−18	−26	−22	−21	−20	−18	−7	−19	−9
Discontinued operations	0	0	0	0	0	0	0	0	0	0	0	−2
Net income	−15	−13	−16	−18	−26	−22	−21	−20	−18	−7	−19	−12
EPS, basic	−$1.66	−$1.20	−$1.29	−$1.34	−$2.13	−$1.02	−$0.76	−$0.73	−$0.54	−$0.30	−$0.37	−$0.22
EPS, diluted	−$1.66	−$1.20	−$1.29	−$1.52	−$2.13	−$1.02	−$0.76	−$0.73	−$0.38	−$0.30	−$0.37	−$0.22
Weighted average shares, basic	9	12	12	12	12	27	27	27	49	48	50	52
Weighted average shares, diluted	9	12	12	12	12	27	27	27	49	48	50	52
EBITDA	−12	−11	−13	−15	−21	−16	−17	−9	−6	1	−7	−1
Depreciation & amortization	2	1	2	2	3	3	3	4	4	2	5	2
EBIT	−14	−12	−15	−17	−24	−19	−20	−13	−11	−1	−11	−3